[Articles] Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia
In patients with previously treated chronic lymphocytic leukaemia, PVR showed significant improvement in progression-free survival compared with VR, with consistent results in patients who had previously received covalent BTK inhibitors and no new safety signals. To our knowledge
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.